Controversies in Management of Patent Ductus Arteriosus in the Preterm Infant

Bharati Sinha*
Assistant professor in Pediatrics, Boston University School of Medicine, USA

Abstract

The management of patent ductus arteriosus in the preterm infant is one of the areas of clinical care that is subjected to great practice variation. This is sadly one of the consequences of widespread adoption of closure of the patent ductus arteriosus by pharmacological or surgical means without subjecting the treatment approaches to rigorous randomized control trials. The diverse approaches to treatment currently range from early and aggressive closure of the ductus arteriosus to a conservative approach of watchful waiting for spontaneous closure. This review reviews the complex management strategies of the ductus arteriosus highlighting the areas of greatest controversy that need to be addressed in future trials to provide greatest benefit to the vulnerable preterm infant.

Keywords: Patent ductus arteriosus; PDA; Preterm; Indomethacin; Ibuprofen; Ligation

Introduction

Patent Ductus Arteriosus (PDA) is the most common cardiovascular abnormality in preterm neonates with a reported incidence as high as 60% in Extremely-Low-Birth-Weight (ELBW) newborns less than 28 weeks gestation [1]. While the Ductus Arteriosus (DA) is important for prenatal and immediate postnatal circulation, its persistence beyond the transitional period is associated with neonatal morbidity and mortality [2]. However, there is little evidence of consistent effect of treatment of PDA on major preterm morbidities and aggressive attempts to close the DA is now being questioned [3,4]. The exact population of preterm babies that benefit from PDA treatment is unknown. Whether or not PDA should be treated, the timing of PDA treatment, mode, dose and duration of therapy is increasingly becoming a subject of great controversy.

Historical Perspective

The DA is uniquely positioned in the history of medicine. Its presence was originally recognized by Galen in the 2nd century AD and recorded in his anatomic compendia [5]. However, Galen and other early anatomists formed erroneous conclusions about the fetal and adult circulation and it was not until the 16th century that the DA was more accurately described [6,7]. The first surgical ligation of PDA performed in 1938 by Robert E. Gross of Boston Childrens Hospital heralded the true beginning of the field of congenital heart surgery [8]. The knowledge that prostaglandins were responsible for ductal patency, produces more prostaglandin and is also more sensitive to the relaxant effect of PGE2 and nitric oxide [14]. Even when the premature ductus does constrict, it remains relatively resistant to developing profound subendothelial hypoxia that stimulates cell death and remodeling. Delayed ductal closure is related to prematurity and exaggerated by comorbidities such as respiratory distress syndrome and sepsis. A genetic basis for ductal patency has also been suggested by mutations and polymorphisms within genes interfering with remodeling of vascular smooth muscle cells of ductal media [15].

Natural History of PDA

With the widespread use of medical and surgical strategies to close the DA since the 1970s, the natural history of DA is less well known. Historical observational studies in the 1960s have reported spontaneous delayed closure in premature infants [16,17]. In a prospective observational study of 65 infants with BW<1500 g, spontaneous DA closure occurred by 1 week of age in approximately one-third of preterm babies with BW of <1000 g and two thirds of babies >1000g [18]. In this study, in babies >1000g, 94% of DA closed prior to discharge. The median time to spontaneous closure was 7 days for infants >1000 g versus 56 days for infants ≤1000 g. Among a select group of VLBW...
infants with a persistent PDA at initial hospital discharge either from non-treatment or re-opening following initial treatment, spontaneous closure was common, occurring in the majority of infants, and usually occurring within several months of discharge [19]. After adopting a "conservative" approach to treatment of PDA, a cohort-controlled study in preterm infants <28 weeks gestation showed that of the 1/3rd of the conservatively treated infants where PDA remained open, 2/3rd of these infants ultimately closed their duct either prior to discharge or before 6 months of life while 1/3rd needed closure in infancy via transcatheter coil embolization [20].

The spontaneous closure of PDA can be affected adversely by several perinatal and postnatal events, including growth restriction [21], late onset sepsis [22], low platelets [23] and excessive fluid administration during the first days of life [24]. Although surfactant itself has no direct effect on ductal hemodynamics [25], it may alter the pulmonary vascular resistance and lead to an earlier clinical presentation of the left-to-right shunt through the PDA [26].

Diagnosis of PDA

PDA presents clinically in the preterm infant as systolic murmur, bounding peripheral pulses, hyperactive precordium and wide pulse pressure. Echocardiography is used as the gold standard for diagnosis of PDA. The PDA is often clinically silent in the first 24 hours of birth. A blinded comparison of clinical and echocardiographic parameters in a cohort of preterm infants showed that the signs of bounding pulses, active precordium, and systolic murmur were of reasonable specificity but very low sensitivity in the first 3 to 4 days of birth for diagnosis of an echocardiographically defined significant PDA [27]. The study also showed that relying on clinical signs alone led to a mean diagnostic delay of 2 days. Other studies have similarly reported that precision and accuracy of clinical and radiological signs of a PDA with left-to-right shunting are unsatisfactory [28] highlighting the importance of echocardiography for a reliable early diagnosis of PDA. Repeated clinical examinations combined with serial echocardiography is an important practice for early detection and management of the PDA.

Clinical Consequences of PDA

A significant left-to-right shunting through the PDA may result in pulmonary overcirculation leading to clinical outcomes like pulmonary hemorrhage [29,30], RDS [31], and chronic lung disease [32]. It also steals blood away from the systemic circulation resulting in adverse consequences of necrotizing enterocolitis [33] intraventricular hemorrhage [34] periventricular leukomalacia [35], cerebral palsy [36] and death [37]. Although observational studies have consistently shown an association with the above adverse outcomes, there is lack of evidence whether PDA is truly causal or simply an association. Meta-analysis of trials assessing benefits of treatment have depicted no detectable reduction in neonatal morbidities [2]. This may be partly because the treatment themselves have adverse effects and added morbidities. Moreover some of the physiological explanations to the outcomes may be an oversimplification and do not take the adaptive mechanisms into account. For instance even in the presence of high ductal shunt volume, upper body blood flow may be relatively well maintained in infants outside the transitional period [38].

Clinical Versus Hemodynamic Significance

There is no consensus over the criteria to quantify the hemodynamic significance of the duct or appropriate treatment. The size of the ductus, the pattern of left to right shunt, volume of shunting causing left atrial dilatation and flow pattern in descending aorta are among the few parameters quantifying the hemodynamically significant PDA (hsPDA) [39]. Harling et al. [40] found that among a range of echocardiographic criteria studied the ductus diameter appears to be the most important variable in determining the need for therapeutic intervention. Su et al. [41] described a sequence of pattern changes from pulmonary hypertension pattern to growing pattern or pulsatile pattern in those with clinically significant PDA. Pulsatile pattern had a sensitivity of 93.5% and specificity of 100% in predicting hsPDA. An increasing number of biomarkers representing cardiac stress, dysfunction or myocardial injury like Brain Natriuretic Peptide (BNP) are also emerging as diagnostic and prognostic markers for hsPDA [42] but they lack the sensitivity and diagnostic specificity to be clinically useful.

How much of this hemodynamic significance of PDA translates to clinical significance is currently unknown. Ductal shunting has been shown to be independently related to short term but not long term respiratory outcomes [43]. Similarly, a strong association was noted between early ductal size and Intraventricular Haemorrhage (IVH), probably mediated through low SBF [44]. More studies are needed to demonstrate hemodynamic consequence of hsPDA on long term neonatal outcomes. McNamara and Sehgal have proposed an individualistic and rational approach to treatment that combines echocardiographic assessment with clinical parameters [45].

Management of PDA

Treatment modalities

Watchful waiting for spontaneous closure: This has recently emerged as an option following emergence of evidence that current medical and surgical therapy does not improve the outcome that was intended by treatment. In older preterm infant with BW>1000 g with uncomplicated respiratory course where the likelihood of spontaneous closure is high, this may be the most prudent approach. While awaiting spontaneous closure, a strategy applied to infants with left to right shunt associated with congenital cardiac malformations has been proposed by some investigators [3]. This includes judicious fluid restriction and diuretics for congestive heart failure; use of minimal supplemental oxygen, permissive hypercapnia, avoidance or correction of metabolic alkalosis to minimize pulmonary vasodilation and application of continuous distending airway pressure to reduce pulmonary blood flow and increase systemic perfusion.

Medical therapy

Choice of drug: Cyclo-oxygenase inhibitors such as indomethacin and ibuprofen remain the mainstay of medical therapy. Indomethacin is most widely used but Ibuprofen is now being recommended as the drug of choice owing to reduction in the risk of NEC and transient renal insufficiency [46]. Success of PDA closure by paracetamol in a limited number of extreme preterm neonates have been reported [47], but further studies are needed to confirm its effectiveness and safety when used for this indication.

Adverse effects: Unfortunately the medical therapy of PDA is not without side effects. Little et al. [48] reviewed the clinical course of 167 infants treated with indomethacin in a symptomatic PDA, and noted adverse effects in 73% of patients. Indomethacin therapy was associated with thrombocytopenia (36%), azotemia (31%), sepsis (30%), oliguria (25%), hyponatraemia (25%), IVH (16%), pulmonary interstitial emphysema (11%), NEC (8%), intestinal perforation (4%) and bleeding (3%). Similar adverse effects have been reported in other studies and it has been additionally shown that Ibuprofen may be associated with
lower serum creatinine values, higher urine outputs and less adverse peripheral vasoconstrictive effects compared to Indomethacin [49].

**Dose and administration:** Indomethacin is classically administered as 3 bolus doses at 12 h intervals although several different regimens for both Indomethacin and Ibuprofen have been described [50]. Indomethacin mediated reduction in systemic blood flow may be ameliorated by slowing the infusion rate to 20-30 minutes [51] or by continuous administration [52]. Rather than following a fixed dosing schedule, an indomethacin treatment strategy based on serial echocardiographic measurements of PDA flow pattern is associated with reduction in total doses of drug while being equally effective [41].

**Number of courses:** Studies using more than 2 courses of indomethacin are few with some evidence of increasing renal toxicity with increased doses. In a retrospective study, Sangem et al. [53,54] observed a 42% response rate after a second course of indomethacin and a 43%, with the third course of indomethacin, yielding a cumulative response rate to 3 courses of indomethacin of 90%. However, a higher increase of periventricular leukomalacia in those who received a 3rd course of indomethacin does raise some concern. Like Indomethacin, the closure rate of PDA after a second or third course of ibuprofen was similar to the closure rate after the first course but not associated with an increase in adverse effects [54].

Clinical factors that have been associated with permanent duc tal closure in response to pharmacologic therapy include exposure to antenatal steroids, the absence of significant respiratory distress, reduced fluid intake, postnatal age at the time of treatment, and a longer duration of indomethacin treatment.

**Surgical treatment:** Surgical ligation is commonly used if medical therapy fails to close a significant PDA or contraindications exist to medical therapy. There is a high rate of variation in the rates of surgical ligation across the world with up to 24% of babies less than 27 weeks of gestation subjected to ligation in North America compared to 10% ligation rate in Australian units [55]. Surgical closure of the PDA involves either placement of suture ligatures or application of vascular clips. Clip application is a shorter procedure, requires less extensive dissection and therefore may be the preferred method of surgical closure [56]. Postoperative morbidities of PDA ligation include thoracotomy, NEC, IVH, wound infection, chylothorax, pleural effusion and vocal cord dysfunction [57]. Although the overall morbidity due to the procedure itself is low, it may entail transfer to another facility or operating room posing a significant burden to the fragile ELBW infant. Moreover, surgical ligation is often associated with impaired left ventricular systolic function, sometimes resulting in circulatory and respiratory collapse requiring marked escalation in intensive care support [58]. The postoperative cardiorespiratory instability may be reduced when ligation is delayed [59].

**Timing of treatment**

Timing of PDA treatment can be grouped as (1) Prophylactic (2) Presymptomatic (3) Early Symptomatic (4) Late symptomatic.

**Prophylactic treatment**

This involves giving treatment prophylactically within the first 24 h according to defined gestation or weight-based criteria. Indomethacin is the best studied with 2872 babies randomised in 19 trials [60]. This meta-analysis showed that prophylactic indomethacin reduced the incidence of major IVH and PVL but did not affect mortality or long-term neurodevelopmental outcome. Prophylactic PDA ligation may reduce NEC [61] but increases the incidence of BPD [62]. Given the lack of effect on long term outcomes, evidence of spontaneous closure of DA in almost 1/3rd of VLBWs, potential vasoconstrictive effects of Indomethacin in other peripheral vascular beds, prophylactic therapy cannot be universally recommended.

**Pre-symptomatic treatment**

This relies on echocardiography for diagnosis of PDA before it is clinically apparent. Investigators have also used biochemical markers like B-type atrial natriuretic peptide (BNP) levels at 24 h of age to guide for early targeted treatment of hspPDA and avoid the unnecessary use of cyclooxygenase inhibitors in ELBW infants [63]. A comparison of early (day 3) with late (day 7) intravenous indomethacin in a prospective multicenter trial improved PDA closure rates but was associated with increased renal side effects and more severe complications in early treatment group while offering no respiratory advantage over late indomethacin administration in ventilated, surfactant-treated infants [64]. Similarly, Aranda et al. [65] did not show a difference in outcome with treatment of non-symptomatic PDA within 72 h of life in ELBW infants with ibuprofen or placebo based on echocardiographic criteria. Champions of early treatment of PDA have argued that day 3 may still be too late as the hemodynamic consequences of large duct are apparent within a few hours of birth. However, Indomethacin given to premature infants with a large ductus in the first hours of life detected by echocardiography showed no positive or negative effects on blood flow to the brain and upper body [66]. The results of the DETECT (Ductal Echocardiographic Targeting & Early Closure Trial) trial; targeting treatment to large ducts within the first 12 h of life are awaited [67].

**Symptomatic treatment**

The symptomatic approach, although most commonly used, is most difficult to classify due to variation in attributing clinical significance to presence of murmur to varying degrees of ventilator dependency or cardiovascular compromise. The evidence for this approach is mostly from a large historical trial that recommended administration of indomethacin only when non pharmacological supportive treatment fails as this was associated with fewer side effects [67]. With advancing postnatal age, dilator prostaglandins play less of a role in maintaining ductus patency, and indomethacin becomes less effective in closing PDA [68]. In infants who failed indomethacin treatment, an “aggressive approach” of early surgical ligation (within 2 days) compared with “conservative approach” of delaying ligation till development of significant cardiorespiratory compromise showed no significant differences in the rates of BPD, sepsis, ROP, neurologic injury, or mortality in a cohort controlled study [20]. The risk for NEC was significantly less in the conservatively treated infants, even though they received enteral feedings in the presence of a PDA.

**Conclusion and Future Directions**

The variation in management of PDA due to conflicting evidence that it truly impacts the long-term outcome brings a sense of urgency to conduct robust trials that could identify which group of preterm infants benefit most from early treatment of PDA and which group can be managed expectantly with watchful waiting or delayed treatment. Lack of benefit of PDA treatment on major neonatal outcomes may relate to the lack of standardization of diagnosis of hemodynamic significance, variability in timing of intervention and diagnosis, difference in therapeutic regime, and failure of consideration of co-morbidities. A scoring system that combines echocardiographic, clinical and lab criteria of PDA that correlate with adverse outcome and is subsequently validated in a well designed trial will go a long way in standardizing care and improving outcomes in this vulnerable population. Until more
References
1. Van Overmeire B, Chemtob S (2005) The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 10: 177-184.
2. Herms-DeSantis ER, Clyman RI (2006) Patent ductus arteriosus: pathophysiology and management. J Perinatol 26: S14-18.
3. Benitz WE (2010) Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 30: 241-252.
4. Laughon MM, Simmons MA, Bose CL (2004) Patency of the ductus arteriosus in the premature infant: is it pathological? Should it be treated? Curr Opin Pediatr 16: 146-151.
5. Franklin KJ (1941) A survey of the growth of knowledge about certain parts of the foetal cardio-vascular apparatus, and about the foetal circulation, in man and some other mammals. Part I: Galen to Harvey. Ann Sci 5: 57-89.
6. SIEGEL RE (1962) Galen’s experiments and observations on pulmonary blood flow and respiration. Am J Cardiol 10: 738-745.
7. Reese J (2012) Patent ductus arteriosus: mechanisms and management. Semin Perinatol 36: 89-91.
8. Gross RE, Hubbard JP (1984) Landmark article Feb 25, 1939: Surgical ligation of a patent ductus arteriosus. Report of first successful case. By Robert E. Gross and John P. Hubbard. JAMA 251: 1201-1202.
9. Friedman WF, Hirschklau MJ, Prinz MP, Pitlick PT, Kirkpatrick SE (1976) Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 295: 530-533.
10. Heymann MA, Rudolph AM, Silverman NH (1976) Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 295: 530-533.
11. Stoller JZ, Demua SB, Dagle JM, Reese J (2012) Current Perspectives on Pathobiology of the Ductus Arteriosus. J Clin Exp Cardiol 5.
12. Cocceni F, Baragatti B (2012) Mechanisms for ductus arteriosus closure. Semin Perinatol 36: 92-97.
13. Yokoyama U, Minamisawa S, Quan H, Ghatak S, Akaile T, et al. (2006) Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 116: 3026-3034.
14. Smith GC (1998) The pharmacology of the ductus arteriosus. Pharmacol Rev 50: 35-56.
15. Dagle JM, Lepp NT, Cooper ME, Schaa KL, Kelsey KJ, et al. (2009) Determination of genetic predisposition to patent ductus arteriosus in preterm infants. Pediatrics 123: 1116-1123.
16. Hallidie-Smith KA (1972) Murmur of persistent ductus arteriosus in premature infants. Arch Dis Child 47: 725-730.
17. Clarkson PM, Ogiliv AA (1974) Continuous murmurs in infants of low birth weight. J Pediatr 84: 208-211.
18. Nemerofsky SL, Parravincini E, Bateeman D, Kleinman C, Polin RA, et al. (2008) The ductus arteriosus rarely requires treatment in infants > 1000 grams. Am J Perinatol 25: 661-666.
19. Hermann K, Bose C, Lewis K, Laughon M (2009) Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child Fetal Neonatal Ed 94: F48-50.
20. Jhaveri N, Moon-Grady A, Clyman RI (2010) Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. J Pediatr 157: 381-387.
21. Rakza T, Magnenat E, Klosowski S, Tourneux P, Bachiri A, et al. (2007) Early hemodynamic consequences of patent ductus arteriosus in preterm infants with intraventricular growth restriction. J Pediatr 151: 624-628.
22. González A, Sosenko IR, Chandar J, Hummler H, Claire N, et al. (1996) Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 128: 470-478.
23. Eckher K, Stark K, Lorenz M, Kerstan S, Walch A, et al. (2010) Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med 16: 75-82.
24. Bell EF, Acarregui MJ (2001) Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants [Review]. Cochrane Database Syst Rev CD000503.
25. Fujii A, Allen R, Doros G, O’Brien S (2010) Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome. J Perinatol 30: 671-676.
26. Käläppä P, Seppäläinen M, Kero P, Saraste M (1993) Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr 123: 115-119.
27. Skelton R, Evans N, Smythe J (1994) A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 30: 406-411.
28. Davis P, Turner-Gomes S, Cunningham K, Way C, Roberts R, et al. (1995) Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatr Adolesc Med 149: 1136-1141.
29. Finlay ER, Subhedar NV (2000) Pulmonary haemorrhage in preterm infants. Eur J Pediatr 159: 870-871.
30. Kluckow M, Evans N (2000) Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 137: 68-72.
31. Jones RW, Pickering D (1977) Persistent ductus arteriosus complicating the respiratory distress syndrome. Arch Dis Child 52: 274-281.
32. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kryuer L, et al. (1999) Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 104: 1345-1350.
33. Dolkberg S, Lusky A, Reichman B (2005) Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 40: 184-188.
34. Evans N, Kluckow M (1996) Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 75: F183-186.
35. Shortland DB, Gibson NA, Levene MI, Archer LN, Evans DH, et al. (1990) Patent ductus arteriosus and cerebral circulation in preterm infants. Dev Med Child Neurol 32: 386-393.
36. Drougia A, Giapros V, Kraulis N, Theocharis P, Nikaki A, et al. (2007) Incidence and risk factors for cerebral palsy in infants with perinatal problems: a 15-year review. Early Hum Dev 83: 541-547.
37. Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, et al. (2009) Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 123: e138-144.
38. Broadhouse KM, Price AN, Durighel G, Cox DJ, Finnemore AE, et al. (2013) Assessment of PDA shunt and systemic blood flow in newborns using cardiac MRI. NMR Biomed 26: 1135-1141.
39. Skinner J (2001) Diagnosis of patent ductus arteriosus. Semin Neonatol 6: 49-61.
40. Harling S, Hansen-Pupp I, Baigi A, Pesonen E (2011) Echocardiographic prediction of patent ductus arteriosus in need of therapeutic intervention. Acta Paediatr 100: 231-235.
41. Su BH, Peng CT, Tsai CH (1999) Echocardiographic flow pattern of patent ductus arteriosus: a guide to indomethacin treatment in premature infants. Arch Dis Child Fetal Neonatal Ed 81: F197-200.
42. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, et al. (2005) Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 25: 709-713.
43. Evans N, Iyer P (1995) Longitudinal changes in the diameter of the ductus arteriosus in ventilated preterm infants: correlation with respiratory outcomes. Arch Dis Child Fetal Neonatal Ed 72: F156-161.
44. Evans N, Kluckow M (1996) Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 75: F183-186.
45. McNamara PJ, Sehgal A (2007) Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 92: F424-427.
46. Ohlsson A, Walia R, Shah SS (2013) Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 4: CD003481.
47. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, et al. (2011) Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrica 128: e1618-1621.

48. Little DC, Pratt TC, Blalock SE, Krauss DR, Cooney DR, et al. (2003) Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg 38: 492-496.

49. Thomas RL, Parker GC, Van Overmeire B, Aranda JV (2005) A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 164: 135-140.

50. Mezu-Ndubuisi OJ, Agarwal G, Raghavan A, Pham JT, Ohler KH, et al. (2012) Patent ductus arteriosus in premature neonates. Drugs 72: 907-916.

51. Simko A, Mardoum R, Merritt TA, Bejar R (1994) Effects on cerebral blood flow velocities of slow and rapid infusion of indomethacin. J Perinatol 14: 29-35.

52. Christmann V, Liem KD, Semmekrot BA, van de Bor M (2002) Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr 91: 440-446.

53. van der Lugt NM, Lopriore E, Bokenkamp R, Smits-Wintjens VE, Steggerda SJ, et al. (2012) Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus. Eur J Pediatr 171: 873-877.

54. Evans N (2012) Preterm patent ductus arteriosus: should we treat it? J Paediatr Child Health 48: 753-758.

55. Mandhan PL, Samarakkody U, Brown S, Kukkady A, Maatte K, et al. (2006) Comparison of suture ligation and clip application for the treatment of patent ductus arteriosus in preterm neonates. J Thorac Cardiovasc Surg 132: 672-674.

56. Raval MV, Laughon MM, Bose CL, Phillips JD (2007) Patent ductus arteriosus ligation in premature infants: who really benefits, and at what cost? J Pediatr Surg 42: 69-75.

57. Noori S, Friedlich P, Seri I, Wong P (2007) Changes in myocardial function and hemodynamics after ligation of the ductus arteriosus in preterm infants. J Pediatr 150: 597-602.

58. Teixeira LS, Shivananda SP, Stephens D, Van Arsdel G, McNamara PJ (2008) Postoperative cardiorespiratory instability following ligation of the preterm ductus arteriosus is related to early need for intervention. J Perinatol 28: 803-810.

59. Fowlie PW, Davis PG, McGuire W (2010) Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev CD000174.

60. Mosali R, Alfaleh K, Paes B (2009) Role of prophylactic surgical ligation of patent ductus arteriosus in extremely low birth weight infants: Systematic review and implications for clinical practice. Ann Pediatr Cardiol 2: 120-126.

61. Clyman R, Cassady G, Kirklin JK, Collins M, Philips JB 3rd (2009) The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 154: 873-876.

62. Kim JS, Shim EJ (2012) B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants. Korean Circ J 42: 192-196.

63. Van Overmeire B, Van de Broek H, Van Laer P, Weyler J, Vanhaezebrouck P (2001) Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 138: 205-211.

64. Aranda JV, Clyman R, Cox B, Van Overmeire B, Wiznia P, et al. (2009) A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. Am J Perinatol 26: 235-245.

65. Osborn DA, Evans N, Kluckow M (2003) Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Arch Dis Child Fetal Neonatal Ed 88: F477-482.

66. Gersony VM, Peckham GJ, Elliott RC, Miettinen OS, Nadas AS (1983) Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 102: 895-906.

67. Acharya B, Yeh TF, Pilides RS (1996) Indomethacin therapy in infants with advanced postnatal age and patent ductus arteriosus. Clin Invest Med 9: 250-253.